Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 1,001–1,100 of 3,704
Swift, D. L., Ross, L. M., Laddu, D. R., Conroy, M. B., German, C. A., Evangelista, L. S., Marvel, F. A., Jerome, G. J., on behalf the American Heart Association Council on Lifestyle and Cardiometabolic Health, Council on Cardiovascular and Stroke Nursing, et al. (2026) · Circulation · doi:10.1161/cir.0000000000001441 · Cited by 13
Naude, J., Zentner, A., Suresh, P., Bittman, J., & Khan, N. A. (2024) · International Journal of Obesity · doi:10.1038/s41366-024-01526-2 · Cited by 13
“…the bupropion/naltrexone augmentation should be examined, to identify patient populations wherein this may be of greatest bene fi t. Future studies should also examine how other agents with demonstrated weight loss potential (i.e. SGLT2 inhibitors) can be used in combination with GLP-1 analogues.”
RetractedReview on obesity management: diet, exercise and pharmacotherapy
Peri, K., & Eisenberg, M. (2024) · BMJ Public Health · doi:10.1136/bmjph-2023-000246 · Cited by 13
“58 In this study, 2539 adults with a BMI of >30 or >27 with one weight-related comorbidity were administered weekly injections of Mounjaro for a period of 72 weeks.”
Viljoen, A., Pantalone, K. M., Galindo, R. J., Cui, X., Huh, R., Hemmingway, A., Fernández Landó, L., & Patel, H. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01398-1 · Cited by 11
“5%, respectively, after 72 weeks of treatment [16].”
BackgroundExercise for Clients Taking an Anti-Obesity Medication
Rogers, R. J. (2024) · ACSM'S Health & Fitness Journal · doi:10.1249/fit.0000000000000959 · Cited by 12
Tirzepatide: Clinical review of the twincretin injectable
Krauss, Z., Hintz, A., & Fisk, R. (2023) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxad080 · Cited by 12
Effect of pharmacist interventions on the management of overweight and obesity: A systematic review
Alhomoud, I. S., Cook, E., Patel, D., Brown, R. E., & Dixon, D. L. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.102058 · Cited by 14
Tronieri, J. S., Ghanbari, E., Chevinsky, J., LaFata, E. M., Minnick, A. M., Rajpal, S., Wang, S. Y., Burcaw, K., Berkowitz, R. I., & Wadden, T. A. (2025) · Nature Medicine · doi:10.1038/s41591-025-03556-3 · Cited by 12
“In particular, recommendations to first undergo a course of BT may need to be modified in the context of newer AOMs (for example, semaglutide and tirzepatide) that produce mean weight losses that are substantially greater than those of even strong responders to BT 26–28 .”
A review on manganese and its effect on health and distribution in selected African countries
Ainyanbhor, I. E., Edo, G. I., Akpoghelie, P. O., Owheruo, J. O., Gaaz, T. S., Yousif, E. A., Isoje, E. F., Igbuku, U. A., Opiti, R. A., Essaghah, A. E. A., et al. (2025) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2025.127707 · Cited by 16
Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea
D’Annibale, D. A., Mimoto, M. S., McCowen, K. C., & Malhotra, A. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001208 · Cited by 13
Incretin receptor agonism rapidly inhibits AgRP neurons to suppress food intake in mice
McMorrow, H. E., Cohen, A. B., Lorch, C. M., Hayes, N. W., Fleps, S. W., Frydman, J. A., Xia, J. L., Samms, R. J., & Beutler, L. R. (2025) · Journal of Clinical Investigation · doi:10.1172/jci186652 · Cited by 12
Kennedy, S. F., Knights, A. W., Ravussin, É., Sánchez‐Delgado, G., Nishiyama, H., Qian, H., Pratt, E. J., Miličević, Z., Haupt, A., Coşkun, T., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70063 · Cited by 17
Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review
Alsuwailem, O. A., Alanazi, R. H., Al-Mutairi, H. A., Asiree, R. H., Almutairi, W., Almutairi, T. M., Zamandar, A., & Alkhames, S. (2025) · Cureus · doi:10.7759/cureus.92454 · Cited by 24
“Table 1 illustrates a total of 2,905 adult patients included in this review, distributed across two retrospective studies in the USA, two case reports in the USA, and one multicenter, randomized controlled trial [15-19].”
Ben‐Porat, T., Dagan, S. S., Côté, M., Miner, C. J., & Buch, A. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100522 · Cited by 18
Effects of weight-loss interventions on bone health in people living with obesity
Paccou, J., Gagnon, C., Yu, E. W.-Y., & Rosen, C. J. (2025) · Journal of Bone and Mineral Research · doi:10.1093/jbmr/zjaf135 · Cited by 18
Al‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
The effect of obesity interventions on male fertility: a systematic review and meta-analysis
Peel, A., Lyons, H. E., Tully, C. A., Vincent, A. D., Jesudason, D. R., Wittert, G., & McPherson, N. O. (2025) · Human Reproduction Update · doi:10.1093/humupd/dmaf025 · Cited by 19
Hsu, Y.-H., Liang, Y.-C., Chan, K.-C., Chou, Y.-H., Wu, H., & Ou, H. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112995 · Cited by 21
Roell, W. C., Alsina‐Fernandez, J., Qu, H., Coşkun, T., Benson, C., Haupt, A., Kelly, R. P., O’Farrell, L. S., Sloop, K. W., Steele, J. P., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102298 · Cited by 13
“…single-molecule dual GIP receptor (GIPR)/GLP-1R agonist tirzepatide has demonstrated reductions in body weight in people with overweight or obesity [6] and shown superior reductions in body weight and glycated hemoglobin (HbA1c) in people with T2D compared with the GLP-1R mono-agonist semaglutide…”
Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists
Wang, Z., Wang, L., Zhang, X., Lowery, B. D., Shaffer, L. L., Chen, Y., Wells, Q. S., Flynn, C. R., Williams, B., Spann, M. D., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.53323 · Cited by 25
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“…Low risk Some concerns Low risk Low risk Some concerns Weghuber et al [30] Randomized Low risk Low risk Low risk Low risk Low risk Jastreboff et al [31] Randomized Low risk Low risk Low risk Low risk Low risk Dahl et al [32] Randomized Low risk Low risk Low risk Low risk Low risk Nahra et al [33]…”
InfluentialSelf-citationNaseralallah, L. M. A., & Aboujabal, B. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2181074 · Cited by 18
“8/100 patient-year in the comparator arms) and headache (ranged between 19% and 36% in the tirzepatide-treated subjects vs 5% to 18% in the comparator arms) were also common adverse events for tirzepatide [7,24,27,28,30,35].”
BackgroundResultInfluentialSridhar, A., Khan, D., Flatt, P. R., Irwin, N., & Moffett, R. C. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130359 · Cited by 12
Shifting paradigms: Reframing coverage of antiobesity medications for plan sponsors
Green, L., & Taddei-Allen, P. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.29.5.564 · Cited by 13
Playdon, M. C., Hardikar, S. S., Karra, P., Hoobler, R., Ibele, A. R., Cook, K. L., Kumar, A., Ippolito, J. E., & Brown, J. C. (2023) · JNCI Monographs · doi:10.1093/jncimonographs/lgad003 · Cited by 14
“…16.4%, and (cid:2) 17.8% for doses of 5mg, 10mg, and 15mg, respectively; 15.3%, 32.3%, and 36.2% of participants randomly assigned to tirzepatide 5mg, 10mg, and 15mg lost at least 25% of body weight compared with 1.5% of subjects randomly assigned to placebo, respectively (all P < .001) (99).”
BackgroundInfluentialLiarakos, A. L., & Koliaki, C. C. (2023) · Biomedicines · doi:10.3390/biomedicines11071875 · Cited by 17
“As expected, the most common side effects were gastrointestinal adverse events mainly occurring during dose escalation [43].”
BackgroundInfluentialThe protective role of GLP-1 in neuro-ophthalmology
Sheth, S., Patel, A., Foreman, M. A., Mumtaz, M., Reddy, A., Sharaf, R., Sheth, S., & Lucke-Wold, B. P. (2023) · Exploration of Drug Science · doi:10.37349/eds.2023.00015 · Cited by 15
The Effective Use of Anti-obesity Medications
Schmitz, S. H., & Aronne, L. J. (2023) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2023.08.003 · Cited by 13
Self-citationObesity and lifespan, a complex tango
Díaz‐Ruiz, A., Price, N. L., Ferrucci, L., & de Cabo, R. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adh1175 · Cited by 12
“Weekly administration of the GLP-1 RA tirzepatide also provided substantial and sustained reductions in body weight ( 52 ).”
BackgroundG protein-coupled receptors and obesity
Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 16
Cardio‐renal‐metabolic disease in primary care setting
Ibrahim, M. A., Ba-Essa, E. M., Baker, J. C., Cahn, A., Ceriello, A., Cosentino, F., Davies, M. J., Eckel, R. H., Gaal, L. V., Gæde, P., et al. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3755 · Cited by 14
“Semaglutide, 44 a GLP ‐ 1RA, has demonstrated an average weight reduction in ~1 year of 16.9% and Tirzepatide, a glucagon ‐ like peptide 1 (GLP ‐ 1) and Gastric inhibitory polypeptide (GIP) dual agonist, 45 has demonstrated average weight reduction in ~1 year of 22.5% in people with obesity.”
BackgroundInfluentialTrends of HbA1c and BMI in People with Type 2 Diabetes: A Japanese Claims-Based Study
Hara, K., Hirase, T., Pathadka, S., Cai, Z., Sato, M., Ishida, N., & Takemura, R. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01543-4 · Cited by 21
“…obesity including lifestyle interventions and pharmacotherapy lead to 3–8.6% weight loss, and invasive procedures such as bariatric surgery reduce 25–30% of body weight within 1–2 years [27, 28], indicating a need for more effective and less invasive treatments targeting obesity in people with T2D.”
InfluentialZeitler, P., Galindo, R. J., Davies, M. J., Bergman, B. K., Thieu, V. T., Nicolay, C., Allen, S., Heine, R. J., & Lee, C. J. (2024) · Diabetes Care · doi:10.2337/dc23-2356 · Cited by 14
Time to Rethink the Approach to Treating Obesity
Samuels, J. M., Patel, M. B., & Niswender, K. D. (2024) · JAMA Surgery · doi:10.1001/jamasurg.2024.1502 · Cited by 11
Weight Gain and Antiretroviral Therapy
Bailin, S. S., & Koethe, J. R. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.04.005 · Cited by 18
Lewis, A., Dodd, M. S., Sourdon, J., Lygate, C. A., Clarke, K., Neubauer, S., Tyler, D. J., & Rider, O. J. (2024) · NMR in Biomedicine · doi:10.1002/nbm.5206 · Cited by 11
Kamrul-Hasan, A. B. M., Mondal, S., Dutta, D., Nagendra, L., Kabir, M. R., & Pappachan, J. M. (2024) · Obesity Science & Practice · doi:10.1002/osp4.70032 · Cited by 23
“Out of the 17 RCTs included in this SRM, one was a phase 1 [24], three were phase 2 [13, 23, 25, 39], and the other 13 were phase 3 trials [26–38].”
InfluentialBernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
“Tirzepatide, an agonist of the glucose-dependent insuli-notropic polypeptide (GIP) and GLP-1 receptor, has shown promising weight-loss effects in patients with and without diabetes [73–75].”
Ketema, E. B., & Lopaschuk, G. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.01.029 · Cited by 19
Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics
Gangwal, A., & Lavecchia, A. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104333 · Cited by 17
Trinh, H., Donovan, A., & McAdam‐Marx, C. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16343 · Cited by 18
“This includes SURMOUNT-1, which established the weight loss efficacy of tirzepatide over 72 weeks in obese patients without diabetes, 9 and preliminary data from SURMOUNT-5, a head-to-head trial comparing tirzepatide to semaglutide over 78 weeks in overweight/obesity patients without diabetes.”
Hunter, T. M., Cao, D., Zhang, X. M., Xavier, N., Poon, J. L., & Fitch, A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01723-w · Cited by 20
“Results from the SURMOUNT-1 trial showed that treatment with tirzepatide (10 or 15 mg) was associated with greater improvements in the SF-36v2 physical functioning scores from baseline to week 72, compared with placebo, among participants with obesity without T2D [11, 33].”
Lambert, G. W., Patel, M., & Lambert, É. (2025) · Metabolites · doi:10.3390/metabo15050286 · Cited by 15
“The recent demonstration of the effectiveness of tirzepatide [118] and retatrutide [119] holds promise for combination therapy targeting GLP-1, GIP, and glucagon to promote weight loss and reduce obesity-related co-morbidities.”
Boakye, E., Grandhi, G. R., Dardari, Z., Adhikari, R., Soroosh, G., Jha, K. K., Dzaye, O. D. A., Tasdighi, E., Erhabor, J., Kumar, S. J., et al. (2023) · Obesity · doi:10.1002/oby.23832 · Cited by 14
Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report
Mendoza, F., & Parsiani, R. (2023) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2023.08.012 · Cited by 17
Goldenberg, R., Teoh, H., & Verma, S. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001084 · Cited by 11
Pharmacological Advances in Incretin-Based Polyagonism: What We Know and What We Don’t
Novikoff, A., & Müller, T. D. (2024) · Physiology · doi:10.1152/physiol.00032.2023 · Cited by 15
An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis
Risi, R., Vidal‐Puig, A., & Bidault, G. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0313 · Cited by 19
“Pointing in this direction, the newly available antidiabetic medication, Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP)/ GLP-1 dual agonist, shows even more valuable effects on glycaemic control and body weight management (Jastreboff et al. 2022).”
BackgroundBąk‐Sosnowska, M., Moszak, M., Doroszewska, A., Wyleżoł, M., Ostrowska, L., & Bogdański, P. (2022) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16351 · Cited by 17
Till, A., Fries, C., & Fenske, W. K. (2022) · Brain Sciences · doi:10.3390/brainsci12121646 · Cited by 14
Retatrutide: A Triple Incretin Receptor Agonist for Obesity Management
Ray, A. (2023) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2023.2276754 · Cited by 11
Moscucci, F., Baratta, F., Pastori, D., Menichelli, D., Mattioli, A. V., Gallina, S., Lospinuso, I., Sciomer, S., Piccirillo, G., & Desideri, G. (2026) · Nutrients · doi:10.3390/nu18040632 · Cited by 11
“Similarly, the SURMOUNT-1 [40] and 2 [41] trials, which evaluated the effects of tirzepatide, revealed even greater weight loss efficacy, with mean reductions in body weight ranging from 15% to 21%.”
Oral semaglutide for the treatment of obesity: a retrospective real-world study
Krajnc, M., Kuhar, N., & Koceva, A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593334 · Cited by 20
“We also observed a signi fi cant decrease in waist circumference that was less than with tirzepatide at all maintenance doses, subcutaneous semaglutide 2.4 mg weekly, and oral semaglutide at a dose of 50 mg daily (19, 20, 27).”
InfluentialChiang, C., Chang, Y., Yu, C.-C., See, X. Y., Wang, T. H., Xanthavanij, N., Song, J., Lo, S., Chiang, C.-H., Lake, L. L., et al. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.020 · Cited by 15
Wu, J., Lin, Y., Hsu, W., Liu, T., Tsai, Y., Huang, P., Chuang, M., Yu, T., & Lai, C. (2025) · Hepatology International · doi:10.1007/s12072-025-10857-9 · Cited by 12
Babazadeh, D., Wyatt, S., & Steinberg, F. M. (2025) · Advances in Nutrition · doi:10.1016/j.advnut.2025.100491 · Cited by 16
“…or Overweight) evaluated the efficacy and safety of tirzepatide noting significant body weight (BW) loss percentages between 12.8% and 18.4% [23 – 28] compared with placebo and bolstering even greater weight loss with tirzepatide than semaglutide in a head-to-head comparison, 20.2% compared…”
InfluentialHydrophobic Tag-Assisted Liquid-Phase Synthesis of Tirzepatide
Pang, Z.-J., Mao, C.-Y., Feng, T., & Dong, L. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c03314 · Cited by 12
Jagtap, U. A., & Paul, A. T. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00373c · Cited by 12
Shukla, A. P., Dunn, J. P., Valderas, E. G., Fraseur, J. G., Karanikas, C. A., & Hunter, T. M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70215 · Cited by 18
“30,34 Quality of life also improved to a greater extent with tirze-patide compared with placebo following over 3 years of treatment in participants with obesity and prediabetes, with improvements in all domains of the SF-36 and the IWQOL-Lite-CT, and most notably physical function.”
Anker, S. D., Ji, L., Kindel, T., Coats, A. J. S., Ojji, D., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2025) · Global Cardiology · doi:10.4081/cardio.2025.86 · Cited by 17
Shah, E., Al-Shiab, R., Abdo, A., Özbek, L., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70713 · Cited by 17
Pratley, R. E., Denham, D. S., Trivedi, R., Watkins, E., Connery, L., Barnes, J., Yu, D., Hong, J., Simard, C., Umans, K., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04440-4 · Cited by 26
“…therapies, including glucagon-like peptide 1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, have substantially improved outcomes for patients, including significant weight loss and reduced risk of adverse cardiovascular events 2,3 .”
Self-citationTirzepatide for Weight Loss: Can Medical Therapy “Outweigh” Bariatric Surgery?
Novograd, J., Mullally, J. A., & Frishman, W. H. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000515 · Cited by 12
Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women
Jones, S., McNeil, M., & Koczo, A. (2023) · Medical Clinics of North America · doi:10.1016/j.mcna.2022.10.008 · Cited by 14
RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis
Jamaluddin, A., & Gorvin, C. M. (2023) · Journal of Molecular Endocrinology · doi:10.1530/jme-23-0014 · Cited by 12
“However, adverse GI effects were reported in diabetic and obese patients indicating that favouring GIP agonism does not remove these adverse effects (Jastreboff et al. 2022).”
BackgroundSeijas‐Amigo, J., Salgado‐Barreira, Á., Castelo-Dominguez, R., Pérez-Álvarez, M. T., Ponce-Piñón, B., Fernández-Silva, M., Rodríguez-Barreiro, M., Pereira-Pía, M., Iglesias-Moreno, J. M., Gago-García, M., et al. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2023.05.004 · Cited by 15
Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
Vishnoi, S., Bhattacharya, S., Walsh, E. M., Okoh, G., & Thompson, D. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00752 · Cited by 14
Stenlid, R., Cerenius, S. Y., Quan, W., Aydın, B. K., Manell, H., Chowdhury, A. I., Kristinsson, H., Ciba, I., Gjessing, E. S., Mörwald, K., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1293093 · Cited by 11
“In addition, the effect of the new GLP-1 and GIP dual agonist tirzepatide (48) and the combination drug of orlistat and acarbose (49) would be immensely interesting to investigate in adolescents with obesity.”
BackgroundRagavan, S., Elhelw, O., Majeed, W., Alkhaffaf, B. H., Senapati, S., Ammori, B. J., Mudaliar, R. N., & Syed, A. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13010256 · Cited by 17
“…approval of incretin-based therapies, including the glucagon-like peptide-1 (GLP1) receptor agonists Liraglutide [11] and Semaglutide [12], and the glucose-dependent insulinotropic polypeptide (GIP) and GLP1 dual agonist Tirzepatide [13], has brought new hope for the medical management of obesity.”
BackgroundHarrington, J., Felker, G. M., Januzzi, J. L., Lam, C. S. P., Lingvay, I., Pagidipati, N. J., Sattar, N. A., Spall, H. G. C. V., Verma, S., & McGuire, D. K. (2024) · Current Cardiology Reports · doi:10.1007/s11886-023-02016-z · Cited by 12
“As with sema-glutide, most side effects were gastrointestinal and led to discontinuations for 6.2% of persons randomized to 15 mg of tirzepatide (vs 2.6% in placebo arm) [61].”
InfluentialAntagonizing GIPR adds fire to the GLP-1R flame
Novikoff, A., & Müller, T. D. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.04.016 · Cited by 12
“The biological dynamics that allow both GIPR co-agonism and complimentary antagonism to synergize with GLP-1R agonism for similar body weight loss remain enigmatic, nonetheless the superior effectiveness of both is undisputed [3,5,7].”
InfluentialObesity and diabetes in heart disease in women
Fatade, Y. A., Dave, E. K., Vatsa, N., Crumbs, T., Calhoun, A. E., Sharma, A., SHUFELT, C. L., & Mehta, P. K. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.30 · Cited by 16
Mortality in relation to diabetes remission in Swedish Obese Subjects – a prospective cohort study
Carlsson, L. M. S., Carlsson, B., Jacobson, P., Karlsson, C., Andersson‐Assarsson, J. C., Kristensson, F. M., Ahlin, S., Svensson, P., Taube, M., Näslund, I., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001807 · Cited by 12
Breakthrough in the Treatment of Metabolic Associated Steatotic Liver Disease: Is it all over?
Petroni, M. L., Perazza, F., & Marchesini, G. (2024) · Digestive and Liver Disease · doi:10.1016/j.dld.2024.04.021 · Cited by 14
Talay, L., Vickers, M., & Loftus, S. (2024) · Telemedicine Reports · doi:10.1089/tmr.2024.0031 · Cited by 13
Data mining study on adverse events of tirzepatide based on FAERS database
Huo, Y., Ma, M., & Liao, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2376686 · Cited by 14
“For instance, in the SURPASS-1 trial, AE rates ranged from 64% to 69%, while in the SURMOUNT-1 study, they escalated to as high as 78.9% to 81.8% [14,16].”
InfluentialAnti-Obesity Medications in Patients With Heart Failure: Current Evidence and Practical Guidance
Harrington, J., Gale, S. E., & Vest, A. R. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011518 · Cited by 11
Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2024) · Obesity · doi:10.1002/oby.24104 · Cited by 13
Incretin-based therapy: a new horizon in diabetes management
Zarei, M., Vaighan, N. S., Farjoo, M. H., Talebi, S., & Zarei, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01479-3 · Cited by 13
“Different randomized clinical trials investigated the efficacy of vari - ous doses of tirzepatide in lowering HbA1c and body weight as monotherapy or add-on therapy to metformin in patients with T2DM when compared to dulaglutide, semaglutide or placebo [73 , 254–257].”
Beetz, N., Kalsch, B., Forst, T. M., Schmid, B., Schultz, A., & Hennige, A. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15984 · Cited by 12
“21 Similarly, the emerging dual glucagon receptor (GCGR)/GLP-1R agonist, survodutide (BI 456906), has also shown promising initial clinical results, with placebo-corrected bodyweight reductions of up to 13.8% reached after only 16 weeks of continuous treatment in participants with a BMI of 27 – 40…”
InfluentialA Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity
Samms, R. J., & Kusminski, C. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022724-105443 · Cited by 12
Fuerlinger, A., Stockner, A., Sedej, S., & Abdellatif, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02566-8 · Cited by 12
Retnakaran, R. R., Ye, C., Kramer, C. K., Hanley, A. J., Connelly, P. W., Sermer, M., & Zinman, B. (2025) · Diabetes Care · doi:10.2337/dc24-1848 · Cited by 15
Theodorakis, N., Nikolaou, M., & Krentz, A. J. (2025) · Biomolecules · doi:10.3390/biom15030373 · Cited by 15
“…agonist) in 2539 adults over 72 weeks, demonstrating dose-dependent weight losses of − 15.0% ( − 15.7 kg), − 19.5% ( − 20.9 kg), and − 20.9% ( − 22.5 kg) with tirzepatide at 5 mg, 10 mg, and 15 mg, respectively, versus − 3.1% ( − 3.2 kg) with a placebo ( p 0.001 for all comparisons) [31].”
InfluentialØstergaard, S., Jessen, C., Paulsson, J. F., Kasimova, M. A., Conde‐Frieboes, K. W., Straarup, E. M., Skyggebjerg, R. B., Ynddal, L., Sanfridson, A., Wulff, B. S., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adq6392 · Cited by 16
What will the impact be of use of tirzepatide in patients with obstructive sleep apnea (OSA)?
Pack, A. I., Grunstein, R. R., Mokhlesi, B., Ryan, S., Schwab, R., & Gozal, D. (2025) · SLEEP · doi:10.1093/sleep/zsaf045 · Cited by 14
Bansal, B., Lajeunesse‐Trempe, F., Keshvani, N., Lavie, C. J., & Pandey, A. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.04.012 · Cited by 28
Incretin-Based Therapies: A Paradigm Shift in Blood Pressure Management?
Dreher, L., Kylies, D., Danser, A. H. J., & Wenzel, U. O. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25112 · Cited by 13
Kommu, S., Sharma, P., & Gabor, R. (2025) · Obesity Reviews · doi:10.1111/obr.13961 · Cited by 17
“The SURMOUNT trials further confirmed tirzepatide's weight loss effects, leading to its FDA approval as a treatment for weight management [7–10].”
Kapan, A., Moser, O., Felsinger, R., Waldhoer, T., & Haider, S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16548 · Cited by 15
Brown, A., Sergent, H., Vu, A. H., Liu, H., Fisher, J. C., Somoza, E., Mei, T., Lipman, J., Park, J., Chui, P., et al. (2025) · Surgical Endoscopy · doi:10.1007/s00464-025-11942-8 · Cited by 14
Song, Z., Tang, Y., Peng, M., Han, R., & He, P. (2025) · Pharmaceuticals · doi:10.3390/ph18091261 · Cited by 19
“Despite the proven efficacy of tirzepatide in glycaemic control and weight reduction, considerable interindividual variability in therapeutic response has been observed [31].”
Allahwala, M. A., Marathe, C. S., Nelson, A. J., Psaltis, P. J., & Marathe, J. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.07.005 · Cited by 17
Insights into the Mechanism of Action of Tirzepatide: A Narrative Review
Galindo, R. J., CHENG, A. Y. Y., Longuet, C., Ai, M., Coşkun, T., Malik, R., Peleshok, J. C., Levine, J. A., & Dunn, J. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01804-w · Cited by 32
“Accordingly, in the overall SURMOUNT-1 study, the mean decrease in waist circumference was 18.5 cm with tirzepatide 15 mg [55].”
InfluentialObesity in CKD: A Promising Path Forward
Friedman, A. N. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09150822 · Cited by 13
Ryan, D. H., Deanfield, J. E., & Jacob, S. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000279 · Cited by 12
A new kind of diabetes medication approved by the FDA: is there hope for obesity?
Dhirani, D., Shahid, A., & Mumtaz, H. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000044 · Cited by 13
“Moreover, ascertaining the weight loss, another recent doubleblinded randomized controlled trial was published in NEJM where all patients intervened for Tirzepatide showed a greater tendency to lose weight when compared with patients taking placebo([7]).”
ResultCVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Schnell, O., Battelino, T., Bergenstal, R. M., Birkenfeld, A. L., Ceriello, A., CHENG, A. Y. Y., Davies, M. J., Edelman, S. V., Forst, T. M., Giorgino, F., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01788-6 · Cited by 13
“Surmount‐1 The SURMOUNT-1 trial [30] evaluated the efficacy and safety of tirzepatide, a GIP and GLP-1 RA versus placebo in adults with overweight or obesity and a BMI of 30 kg/m2 or greater or 27 kg/m2 plus at least one weight-related complication (e.”
BackgroundMethodInfluentialBrethvad, A. O., Zakariassen, H. L., Holt, J., Lundgren, J. R., Jakobsen, A., Hartmann, B., Lehmann, E. W., Kissow, H., Holst, J. J., Madsbad, S., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155534 · Cited by 11
“However, incretin-based pharmacotherapy, leading to almost similar weight loss, has recently been approved [11,12].”
BackgroundObesity management for cardiovascular disease prevention
Hritani, R., Rifai, M. A., Mehta, A., & German, C. A. (2023) · Obesity Pillars · doi:10.1016/j.obpill.2023.100069 · Cited by 15
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.